GLP-1 results on TikTok: what the algorithm hides

What's this video probably claiming?

Without a transcript, we're working from context clues. @the.peppie.co posts in the GLP-1 space, and a caption of a single heart emoji with 35K views suggests this is almost certainly a transformation video, a "my GLP-1 journey" update, or a before-and-after reveal. These formats dominate the semaglutide and tirzepatide corners of TikTok right now. The implicit claim in this genre is consistent: GLP-1 medications produce dramatic, photogenic weight loss that looks like this, on this timeline, with this level of ease. Sometimes creators also fold in claims about appetite suppression being instant, side effects being manageable or rare, or the medication doing the "heavy lifting" while lifestyle stays roughly the same. These are the framings we'll evaluate, because they're the ones with the most clinical daylight between perception and reality.

What does the science actually show?

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that semaglutide 2.4 mg weekly produced mean body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15 mg produced up to 22.5% mean weight loss over 72 weeks. Those are real, significant numbers. But the word "mean" is doing a lot of work. Individual response varies substantially. Roughly 10-15% of participants in semaglutide trials are considered non-responders or minimal responders. Gastrointestinal side effects, nausea, vomiting, constipation, affected over 70% of semaglutide users in STEP trials at some point. And the STEP 4 trial (Rubino et al., 2021, JAMA) showed that stopping semaglutide led to regain of about two-thirds of lost weight within one year. That part rarely makes the TikTok cut.

Where does the social media noise diverge from clinical reality?

The gap is mostly about selection bias and timeline compression. TikTok's algorithm rewards engagement, and engagement spikes on videos showing dramatic change fast. The result is a feed populated almost entirely by people who responded well, lost weight visibly, and hit their results on a compressed timeline. You do not see the people who lost 6% body weight over a year and plateaued. You do not see the people who discontinued due to gastroparesis concerns, which the FDA flagged in 2023 as a potential adverse event warranting label review. You do not see the muscle mass data. A secondary analysis of STEP trials found that roughly 25-39% of weight lost was lean mass, not fat, which is a clinically meaningful finding that almost no GLP-1 content creator addresses. Davies et al. (2021, Diabetes Care) also noted that the metabolic benefits of GLP-1s are real but context-dependent and tied closely to adherence and concurrent lifestyle factors.

What should you actually know?

GLP-1 receptor agonists are legitimately effective medications with strong trial data behind them. That part is not in dispute. But the version of these drugs that lives on TikTok is a curated show reel, not a clinical picture. A few things worth keeping straight: results vary significantly by individual, starting BMI, metabolic health, and adherence. Side effects are common, not rare, and for some people they are serious enough to discontinue. The medications work best as part of a broader plan that includes protein intake and resistance training, specifically to protect lean mass, something the SURMOUNT trials did not fully account for in primary endpoints. Compounded versions of semaglutide and tirzepatide are not equivalent to FDA-approved branded drugs and should not be treated as such. Anyone watching transformation content and making medical decisions based on it is working with incomplete information. Talk to a licensed clinician who has actually read the trials.